Clinical characteristics and outcomes of EZH2-mutant myelodysplastic syndrome: A large single institution analysis of 1774 patients.

导出 LinkOut

翻译打印收藏纠错

第一作者： Somedeb,Ball

第一单位： Division of Hematology and Medical Oncology, University of South Florida/ H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. Electronic address: Somedeb.Ball@moffitt.org.

作者： Somedeb,Ball ^[1] ; Luis E,Aguirre ^[2] ; Akriti G,Jain ^[2] ; Najla Al,Ali ^[3] ; Sara M,Tinsley ^[3] ; Onyee,Chan ^[3] ; Andrew T,Kuykendall ^[3] ; Kendra,Sweet ^[3] ; Jeffrey E,Lancet ^[3] ; David A,Sallman ^[3] ; Mohammad Omar,Hussaini ^[4] ; Eric,Padron ^[3] ; Rami S,Komrokji ^[3]

作者单位： Division of Hematology and Medical Oncology, University of South Florida/ H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. Electronic address: Somedeb.Ball@moffitt.org. ^[1] Division of Hematology and Medical Oncology, University of South Florida/ H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. ^[2] Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. ^[3] Department of Hematopathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. ^[4]

关键词 ASXL1 Deletion 7q EZH2 Hypomethylating agent Overall survival RUNX1